 |
|
|
 |
 |
|
|
 |
|
 |
 |
 |
 |
 |
 |
Frequent questions | |
|
He asks the doctor | |
 |
Beginning | |
 |
 |
 |
|
|
|
|
|
|
|
 |
APOLIPOPROTEÍNAS AND RISK OF CARDIOVASCULAR DISEASES | |
||
|
|
 DEFINITION EVALUATION OF THE RISK TO SEE
| |||
The measurement of plasmatic levels of apolipoproteínas they indicate with reliability the cardiovascular risk, inclusive it can be a more trustworthy indicator of cardiovascular disease than the levels of cholesterol LDL.
Till now there were measuring themselves the concentrations of the cholesterol LDL as the first index of the risk of cardiovascular disease and it is the first target of the treatment with estatinas, but at present the proportion is superior apolipoproteína B / apolipoproteína A-1 to the conventional proportion of cholesterol LDL / HDL in the entire index of cardiovascular risk. This way, the therapy with estatinas guided by the control of the apolipoproteína B can be a more effective scoreboard in the prevention of the cardiovascular diseases that the LDL levels.
The plasmatic concentration of Apo A-I finds limited 15 % and the concentration of Apo B, increased 43 % in patients with myocardium infarction, when the concentration of healthy individuals is compared control.
The relation Apo A-I/B (relation between apolipoproteínas anti-aterogénicas and aterogénicas) limited 40 % in patients with infarction to the myocardium, these levels and his relation show a value discriminante between normal patients and in cardiac risk, with major evidence and clarity that the classic parameters lipídicos and lipoproteícos.
In diverse studies the decrease has been confirmed, sometimes moderate, of Apo A-I and the pronounced and constant increase of the levels of Apo B, in patients with infarction to the myocardium and that generally show vascular complications.The apolipoproteínas evaluation in patients subject to a coronary angiografía has indicated the existence of a strong interrelation of the values Apo A-I and Apo B like the coronary scoreboard that reflects a deterioration of the arterial system. The relation Apo A-I/B must be used not only to identify to subjects with coronary risk, but also like an important index of the severity and progress of the illness ateroesclerótica.
Other evaluations of apolipoproteínas that have been added to the classic determinations of Apo A-I and Apo B for years, are the analyses of Apo A-Il and Apo E but until now a results interrelation does not exist to define a cardiovascular risk.
Apolipoproteina - A1 (Apo A) Risk raised with values low to 130 mg/dl Apolipoproteína B (Apo B) Very weak risk lower than 90 mg/dl Weak risk lower than 115 mg/dl Moderate risk between 115 and 140 mg/dl High risk superior to 140 mg/dl Quotient ApoB / ApoA: Weak risk lower than 0,8 Moderate risk up to 1,2 High risk superior to 1,2
DEFINITION
